Real-time Estimate
Cboe BZX
12:36:23 2024-06-27 EDT
|
5-day change
|
1st Jan Change
|
12.5
USD
|
+2.42%
|
|
+8.88%
|
+32.25%
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,182
|
918.9
|
1,148
|
1,075
|
235.2
|
258.6
|
-
|
-
|
Enterprise Value (EV)
1 |
848.9
|
918.9
|
1,148
|
1,075
|
235.2
|
258.6
|
258.6
|
258.6
|
P/E ratio
|
27.2
x
|
-25.3
x
|
-14.5
x
|
-8.78
x
|
-1.75
x
|
-2.11
x
|
-2.44
x
|
-2.41
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.76
x
|
7.5
x
|
11.8
x
|
12.5
x
|
2.97
x
|
3.71
x
|
3.56
x
|
3.71
x
|
EV / Revenue
|
5.76
x
|
7.5
x
|
11.8
x
|
12.5
x
|
2.97
x
|
3.71
x
|
3.56
x
|
3.71
x
|
EV / EBITDA
|
20
x
|
-49.9
x
|
-13.5
x
|
-11.4
x
|
-2.21
x
|
-2.21
x
|
-2
x
|
-
|
EV / FCF
|
17.9
x
|
163
x
|
-16.2
x
|
-12.4
x
|
-2.1
x
|
-2.07
x
|
-2.11
x
|
-1.42
x
|
FCF Yield
|
5.58%
|
0.61%
|
-6.16%
|
-8.08%
|
-47.7%
|
-48.3%
|
-47.4%
|
-70.4%
|
Price to Book
|
2.56
x
|
2
x
|
2.88
x
|
3.33
x
|
1.09
x
|
1.44
x
|
1.4
x
|
1.77
x
|
Nbr of stocks (in thousands)
|
19,682
|
20,072
|
20,215
|
20,725
|
21,055
|
21,179
|
-
|
-
|
Reference price
2 |
60.08
|
45.78
|
56.81
|
51.87
|
11.17
|
12.21
|
12.21
|
12.21
|
Announcement Date
|
19-11-21
|
20-11-23
|
21-11-22
|
22-11-21
|
23-11-20
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
205.2
|
122.5
|
97.07
|
86.16
|
79.2
|
69.71
|
72.54
|
69.8
|
EBITDA
1 |
59.22
|
-18.42
|
-85.25
|
-93.9
|
-106.6
|
-117
|
-129
|
-
|
EBIT
1 |
36.74
|
-41.64
|
-109.6
|
-123.8
|
-137.2
|
-124.5
|
-110.2
|
-130.3
|
Operating Margin
|
17.9%
|
-34%
|
-112.88%
|
-143.74%
|
-173.23%
|
-178.62%
|
-151.85%
|
-186.63%
|
Earnings before Tax (EBT)
1 |
45.56
|
-35.02
|
-107.6
|
-122.2
|
-131
|
-132.3
|
-118.1
|
-139.3
|
Net income
1 |
46.38
|
-36.17
|
-79
|
-121.8
|
-133.8
|
-123.9
|
-114.8
|
-135.2
|
Net margin
|
22.6%
|
-29.53%
|
-81.38%
|
-141.31%
|
-168.95%
|
-177.74%
|
-158.26%
|
-193.68%
|
EPS
2 |
2.210
|
-1.810
|
-3.920
|
-5.910
|
-6.380
|
-5.798
|
-4.995
|
-5.060
|
Free Cash Flow
1 |
66
|
5.643
|
-70.75
|
-86.91
|
-112.2
|
-125
|
-122.5
|
-182
|
FCF margin
|
32.16%
|
4.61%
|
-72.88%
|
-100.87%
|
-141.67%
|
-179.32%
|
-168.86%
|
-260.76%
|
FCF Conversion (EBITDA)
|
111.45%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
142.3%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-11-21
|
20-11-23
|
21-11-22
|
22-11-21
|
23-11-20
|
-
|
-
|
-
|
Fiscal Period: September |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
---|
Net sales
1 |
27.65
|
18.72
|
19.48
|
20.32
|
23.58
|
17.8
|
18.89
|
18.93
|
18
|
17.05
|
17.41
|
17.12
|
19.6
|
16.23
|
16.08
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-32.14
|
-27
|
-25
|
-
|
-
|
-
|
EBIT
1 |
-30.41
|
-33.85
|
-32.54
|
-27.05
|
-30.01
|
-39.45
|
-36.71
|
-31.03
|
-34.89
|
-32.77
|
-31.47
|
-29.14
|
-26.5
|
-33
|
-36
|
Operating Margin
|
-109.99%
|
-180.85%
|
-167.05%
|
-133.13%
|
-127.25%
|
-221.7%
|
-194.33%
|
-163.9%
|
-193.78%
|
-192.13%
|
-180.83%
|
-170.17%
|
-135.21%
|
-203.3%
|
-223.91%
|
Earnings before Tax (EBT)
1 |
-30.15
|
-33.59
|
-32.15
|
-26.33
|
-29.02
|
-37.61
|
-34.84
|
-29.52
|
-34.03
|
-31.52
|
-34
|
-33.64
|
-30.5
|
-31.5
|
-34.5
|
Net income
1 |
-30.12
|
-33.59
|
-31.7
|
-26.35
|
-28.99
|
-37.66
|
-39.06
|
-28.11
|
-33.41
|
-31.16
|
-32.24
|
-32.19
|
-26.5
|
-31.5
|
-34.5
|
Net margin
|
-108.92%
|
-179.48%
|
-162.74%
|
-129.68%
|
-122.9%
|
-211.62%
|
-206.78%
|
-148.46%
|
-185.56%
|
-182.7%
|
-185.23%
|
-188%
|
-135.21%
|
-194.06%
|
-214.58%
|
EPS
2 |
-1.480
|
-1.630
|
-1.530
|
-1.270
|
-1.390
|
-1.790
|
-1.860
|
-1.330
|
-1.580
|
-1.470
|
-1.466
|
-1.344
|
-1.275
|
-1.500
|
-1.575
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-02-08
|
22-05-09
|
22-08-08
|
22-11-21
|
23-02-07
|
23-05-08
|
23-08-07
|
23-11-20
|
24-02-07
|
24-05-06
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
334
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
66
|
5.64
|
-70.7
|
-86.9
|
-112
|
-125
|
-123
|
-182
|
ROE (net income / shareholders' equity)
|
10.8%
|
-7.88%
|
-18.5%
|
-33.8%
|
-49.7%
|
-58.9%
|
-61.9%
|
-63.7%
|
ROA (Net income/ Total Assets)
|
10.3%
|
-7.41%
|
-17.1%
|
-29.9%
|
-31.9%
|
-29.2%
|
-37.2%
|
-45.6%
|
Assets
1 |
452
|
488
|
462.5
|
407.1
|
418.8
|
424.4
|
308.7
|
296.7
|
Book Value Per Share
2 |
23.50
|
22.80
|
19.70
|
15.60
|
10.30
|
8.500
|
8.700
|
6.880
|
Cash Flow per Share
|
3.410
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
5.42
|
1.45
|
0.75
|
2.13
|
9.06
|
9
|
9
|
-
|
Capex / Sales
|
2.64%
|
1.18%
|
0.77%
|
2.47%
|
11.44%
|
12.91%
|
12.41%
|
-
|
Announcement Date
|
19-11-21
|
20-11-23
|
21-11-22
|
22-11-21
|
23-11-20
|
-
|
-
|
-
|
Last Close Price
12.21
USD Average target price
19.75
USD Spread / Average Target +61.75% Consensus |
1st Jan change
|
Capi.
|
---|
| +32.25% | 259M | | +21.68% | 46.93B | | +37.63% | 39.08B | | -8.15% | 38.48B | | +31.58% | 31.01B | | -13.75% | 26.14B | | +11.36% | 25.88B | | +35.77% | 12.53B | | -6.43% | 11.36B | | -12.27% | 10.65B |
Other Biotechnology & Medical Research
|